Close this search box.

SOMAÍ Pharmaceuticals and Canify Announce Their Partnership to Introduce a Cannabinoid-Based Product Line in Germany

SOMAÍ Pharmaceuticals and Canify AG announce their strategic partnership to introduce a differentiated cannabinoid-based product line in Germany

SOMAÍ Pharmaceuticals Unipessoal LDA (“SOMAÍ”), an EU-GMP European pharmaceutical and biotech company distributing cannabinoid-containing pharmaceuticals globally, announces a landmark three-year marketing & distribution agreement with Canify AG (“Canify”), a licensed pharmaceutical company focussing on medical cannabis. This partnership signifies SOMAÍ Pharmaceuticals’ strategic entry into the German market with a lucrative joint brand-building approach and marks Canify’s portfolio expansion into extracted cannabis products.

This partnership is anticipated to generate an estimated revenue of five million euros over its initial duration, capturing 10% of the German market. A co-branded SOMAÍ-Canify differentiated product line features various ratios of THC/CBD full-spectrum purified oral solutions derived from a single-strain indica non-irradiated premium cultivar. Manufactured and formulated using SOMAÍ Pharmaceuticals technology, the product portfolio is set to be the first of its kind on the German market, with multiple new product lines in plans to be added over the partnership duration. The products are specifically adapted for the German market and will be available for prescription through Canify’s unique distribution platform starting Q3 2024.

Michael Sassano, the Founder, and CEO of SOMAÍ Pharmaceuticals, stated: “The distribution partnership with Canify AG marks a pivotal moment for SOMAÍ Pharmaceuticals, as the entry into the German market serves as the first step in the evolution of our commercial strategy that is set to make SOMAÍ a leading global pharmaceutical brand focused on medical cannabis products. Our commitment to delivering high-quality, innovative medical cannabis products aligns perfectly with Canify’s proven distribution expertise. Together, we’re set to redefine patient care in Germany, embodying our dedication to quality, innovation, and patient well-being.”

Sascha Mielcarek, CEO of Canify AG, adds: “We are excited about entering the partnership with SOMAÍ. Together, we will pave the way for successfully establishing SOMAÍ’s high-quality products in our home market, Germany. With this collaboration, Canify now is in a position to address both relevant segments of the German medical cannabis market, i.e., both flowers and extracts, through its experienced commercial team and to eventually benefit the health of patients in need .”

About SOMAÍ Pharmaceuticals LDA – SOMAÍ Pharmaceuticals is a large-scale EU-GMP manufacturer of cannabis products concentrating on the highest quality medical-grade pharmacological applications. The company invests in the extraction, research, development, formulation, and distribution of EU GMP-pharmaceutical market-authorized cannabinoid products. SOMAÍ is committed to revolutionizing healthcare through cannabis-based treatments. For more information, please visit SOMAÍ’s website.

Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?